The EPO published patent EP3876924A1 filed by Georgetown University claiming pharmaceutical compositions containing CCK inhibitors for treating non-alcoholic steatohepatitis and hepatic fibrosis. The patent application is classified under A61K (pharmaceutical preparations) and A61P (therapeutic activity). Designated states include all EPC contracting states (AL, AT, BE, BG, CH, etc.).

This patent publication provides notice of intellectual property rights that may affect researchers and pharmaceutical companies developing treatments for liver diseases. Parties interested in CCK-inhibitor-based therapies for NASH or hepatic fibrosis should review this patent to assess potential licensing needs or to identify design-around opportunities for their own research programs.